Drug Profile
Research programme: protein-protein interaction inhibitors - Ajinomoto/Interprotein
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ajinomoto; Interprotein Corporation
- Class Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified